MCID: BLD062
MIFTS: 67

Bile Duct Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Bile Duct Cancer

MalaCards integrated aliases for Bile Duct Cancer:

Name: Bile Duct Cancer 12 52 54 42 15
Bile Duct Carcinoma 12 15 17
Extrahepatic Bile Duct Carcinoma 12 15
Extrahepatic Bile Duct Cancer 12 52
Malignant Neoplasm of the Extrahepatic Bile Duct 12
Carcinoma of Extrahepatic Bile Duct 12
Bile Duct Extrahepatic Carcinoma 54
Ca Extrahepatic Bile Ducts 12
Bile Duct Neoplasms 43
Bile Duct Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4606 DOID:4682 DOID:4897
ICD9CM 34 156.1
MeSH 43 D001650
SNOMED-CT 67 363416002 372101000
ICD10 32 C24.0
UMLS 71 C0005396 C0153453 C0238019 more

Summaries for Bile Duct Cancer

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 70567 Definition Cholangiocarcinoma (CCA) is a biliary tract cancer (BTC, see this term) originating in the epithelium of the biliary tree, either intra or extra hepatic. Epidemiology The prevalence is unknown but it accounts for approximately 3% of gastrointestinal tumors and 10-15% of all hepatobiliary malignancies. Clinical description CCA can occur in the intra or extra-hepatic biliary tract. A specific type of extra-hepatic CCA known as a Klatskin tumor (see this term) occurs at the junction where the left and right hepatic bile ducts meet the common bile duct (CBD). It is slightly more prevalent in males than females (1.3:1.0) and usually presents in the fifth to seventh decade of life. Clinical manifestations are not usually noted until an advanced disease stage. Extra-hepatic CCA manifests with signs of cholestasis (jaundice , pale stools, dark urine, pruritus), malaise, weight loss and/or progressive weakness. Intra-hepatic CCA may present with an abdominal mass or with non-specific symptoms of decreased appetite, weight loss, abdominal pain and malaise. Etiology The etiology is unknown and most cases of CCA occur sporadically. Risk factors include primary sclerosing cholangitis (see this term), secondary sclerosing cholangitis, chronic typhoid carriage, parasitic infections (Opisthochis viverrini and Clonorchis sinensis ), exposure to thorotrast (x-ray contrast medium) and choledochal cysts, all of which cause chronic biliary inflammation. Diagnostic methods Diagnosis is suspected on clinical and laboratory findings. Serum carbohydrate antigen (CA) 19-9 is the glycoprotein tumor marker most often used in the diagnosis of CCA. It is found to be elevated in 85% of patients. Increased CEA levels are also noted. Extra-hepatic tumors cause increased levels of alkaline phosphate (ALP), conjugated bilirubin and gamma-glutamyl transpeptidase (GGT) while intra-hepatic have only slightly elevated ALP levels. Abdominal imaging , visualization of the biliary tree and biopsies of the lesion are necessary for diagnosis. Magnetic resonance cholangiopancreatography (MRCP) provides information on intrahepatic metastases, biliary anatomy and tumor extension and is used in the staging of CCA. It has been advocated to replace endoscopic retrograde cholangiopancreatography (ERCP), a more invasive method. Visualization of the biliary tree and samples through brush cytology or bile duct biopsies are obtained with ERCP. A needle biopsy is performed in those with a liver mass. Extra-hepatic CCA is further divided into anatomical subtypes according to the Bismuth classification and a disease stage is given. Ultrasound , and contrast enhanced helical computerized computed tomography (CT) can be used in visualizing the extent of disease. Differential diagnosis Intra-hepatic CCA is often mistaken for metastatic adenocarcinoma. Carcinoma of the gallbladder (see this term), benign strictures and Mirizzi syndrome should be excluded. Management and treatment Surgical resection is the only potentially curative treatment for CCA but recurrences after surgery are frequent. Unfortunately CCA is often diagnosed as unresectable because of local extension and/or metastases. Distal CCA arising from the CBD is often treated by pancreatoduodenectomy. More proximal CCA needs hepatic resection. Palliative management involves biliary drainage by inserting metal stents in the biliary tree to release the blockage. Adjuvant chemotherapy after surgery or palliative chemotherapy for unresectable CCA is indicated. Gemcitabine combined with cisplatin therapy is the standard treatment for unresectable biliary tract cancers, including CCA. Prognosis As proximal CCA is usually not diagnosed until a late stage of disease, prognosis is poor with 5-year survival rates of 20-50% after resection and almost 0% in unresectable tumors. Death is often due to biliary sepsis, cancer cachexia, malnutrition and liver failure. Visit the Orphanet disease page for more resources.

MalaCards based summary : Bile Duct Cancer, also known as bile duct carcinoma, is related to squamous cell bile duct carcinoma and biliary tract cancer. An important gene associated with Bile Duct Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Celecoxib and Analgesics, Non-Narcotic have been mentioned in the context of this disorder. Affiliated tissues include bile duct, liver and skin, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A biliary tract cancer that is located in the bile duct.

MedlinePlus : 42 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile duct outside of the liver is much more common. Risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. Symptoms can include Jaundice Itchy skin Fever Abdominal pain Tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. Treatments include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

Wikipedia : 74 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Bile Duct Cancer

Diseases in the Bile Duct Cancer family:

Bile Duct Carcinoma in Situ

Diseases related to Bile Duct Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 638)
# Related Disease Score Top Affiliating Genes
1 squamous cell bile duct carcinoma 34.7 KRT7 KRT19 CEACAM5
2 biliary tract cancer 33.7 SMAD4 MET EGFR
3 cholangiocarcinoma 33.5 TP53 SMAD4 NCAM1 MIR21 MET KRT7
4 intrahepatic cholangiocarcinoma 33.3 TP53 SMAD4 KRT7 KRT19 KRAS EGFR
5 liver benign neoplasm 33.1 TP53 KRT19 HRAS AFP
6 liver sarcoma 33.1 KRT7 CEACAM5 AFP
7 biliary tract benign neoplasm 32.7 TP53 NCAM1 KRT7 KRT19 KRAS HRAS
8 in situ carcinoma 31.6 TP53 HRAS EGFR CDKN2A CCND1
9 cholangitis, primary sclerosing 31.5 KRT7 KRT19 IL6 AFP
10 tubular adenocarcinoma 31.3 NCAM1 MIR21 KRT7 EGFR CEACAM5 AFP
11 cholecystitis 31.3 TP53 EGFR CDKN2A
12 bile duct cysts 31.2 KRT7 KRT19 KRAS HRAS CEACAM5 AFP
13 gallbladder cancer 31.1 VEGFA TP53 SMAD4 KRT7 KRT19 KRAS
14 bile duct cystadenocarcinoma 31.1 KRT7 CEACAM5 AFP
15 bile duct adenoma 31.1 NCAM1 KRT7 KRT19 CDKN2A
16 krukenberg carcinoma 31.0 KRT7 CEACAM5
17 adenoma 30.9 TP53 SMAD4 KRT7 KRAS CDKN2A CCND1
18 papillary adenocarcinoma 30.9 TP53 MIR21 KRT7 KRT19 KRAS HRAS
19 small cell carcinoma 30.9 TP53 NCAM1 KRT7 KRT19 KRAS EGFR
20 gastrointestinal carcinoma 30.9 TP53 KRT19 IL6 CEACAM5
21 adenocarcinoma 30.9 VEGFA TP53 SMAD4 MET KRT7 KRAS
22 adenosquamous carcinoma 30.9 TP53 SMAD4 KRT7 KRT19 KRAS EGFR
23 villous adenoma 30.9 TP53 KRAS HRAS CEACAM5
24 acinar cell carcinoma 30.8 TP53 SMAD4 KRT7 AFP
25 fibrolamellar carcinoma 30.8 KRT7 KRT19 AFP
26 neuroendocrine carcinoma 30.8 NCAM1 KRT7 KRT19 CEACAM5
27 sclerosing cholangitis 30.8 TP53 IL6 CEACAM5
28 cystadenoma 30.8 KRT7 CEACAM5 CCND1 AFP
29 bile duct adenocarcinoma 30.8 TP53 MIR31 MIR21 KRT7 KRT19 KRAS
30 cystadenocarcinoma 30.8 VEGFA TP53 KRT7 HRAS CEACAM5
31 klatskin's tumor 30.8 KRT7 KRT19 CEACAM5 AFP
32 appendix adenocarcinoma 30.8 KRT7 KRAS HRAS CEACAM5
33 small cell cancer of the lung 30.8 TP53 NCAM1 MIR21 KRT7 KRT19 EGFR
34 pancreatic acinar cell adenocarcinoma 30.8 KRT19 KRAS HRAS AFP
35 pancreatic ductal adenocarcinoma 30.7 VEGFA TP53 SMAD4 MSLN MIR31 MIR21
36 kidney cancer 30.7 VEGFA TP53 MIR21 MET EGFR CDKN2A
37 hepatitis b 30.7 TP53 MIR21 KRAS IL6 AFP
38 bladder cancer 30.7 VEGFA TP53 MIR31 MIR21 KRT19 KRAS
39 pancreatic ductal carcinoma 30.7 VEGFA TP53 SMAD4 MSLN KRT7 EGFR
40 sarcoma 30.7 VEGFA TP53 MET KRAS IL6 HRAS
41 ampulla of vater cancer 30.6 TP53 SMAD4 KRT7 KRAS HRAS CEACAM5
42 papilloma 30.6 VEGFA TP53 KRT7 KRAS FSCN1 EGFR
43 carcinosarcoma 30.6 TP53 KRT7 KRAS HRAS EGFR CEACAM5
44 gallbladder disease 30.6 TP53 KRT7 KRAS HRAS EGFR CEACAM5
45 lynch syndrome 30.6 TP53 SMAD4 MIR31 KRAS HRAS EGFR
46 pancreatitis 30.5 TP53 SMAD4 MIR21 KRAS IL6 HRAS
47 mucinous adenocarcinoma 30.5 VEGFA TP53 KRT7 KRT19 KRAS EGFR
48 bile duct disease 30.4 TP53 KRT7 KRT19 KRAS IL6 HRAS
49 biliary tract disease 30.4 TP53 KRT7 KRT19 KRAS IL6 HRAS
50 renal cell carcinoma, nonpapillary 30.3 VEGFA TP53 MSLN MIR31 MIR21 MET

Graphical network of the top 20 diseases related to Bile Duct Cancer:



Diseases related to Bile Duct Cancer

Symptoms & Phenotypes for Bile Duct Cancer

GenomeRNAi Phenotypes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.91 EGFR HRAS KRAS NCAM1
2 Decreased viability GR00055-A-2 9.91 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 9.91 KRAS
4 Decreased viability GR00106-A-0 9.91 KRAS
5 Decreased viability GR00221-A-1 9.91 EGFR HRAS KRAS
6 Decreased viability GR00221-A-2 9.91 HRAS KRAS
7 Decreased viability GR00221-A-3 9.91 HRAS
8 Decreased viability GR00221-A-4 9.91 EGFR
9 Decreased viability GR00301-A 9.91 KRAS
10 Decreased viability GR00381-A-1 9.91 KRAS
11 Decreased cell migration GR00055-A-1 9.55 MET
12 Decreased cell migration GR00055-A-2 9.55 NCAM1
13 Decreased cell migration GR00055-A-3 9.55 EGFR HRAS NCAM1
14 Reduced mammosphere formation GR00396-S 9.23 AFP CCND1 EGFR HRAS KRAS KRT7

MGI Mouse Phenotypes related to Bile Duct Cancer:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 CCND1 CDKN2A EGFR FSCN1 IL6 KRAS
2 behavior/neurological MP:0005386 10.38 AFP CCND1 CDKN2A FSCN1 HRAS IL6
3 cardiovascular system MP:0005385 10.34 CCND1 CDKN2A EGFR HRAS IL6 KRAS
4 endocrine/exocrine gland MP:0005379 10.34 AFP CCND1 CDKN2A EGFR HRAS IL6
5 mortality/aging MP:0010768 10.34 AFP CCND1 CDKN2A EGFR FSCN1 HRAS
6 digestive/alimentary MP:0005381 10.32 CCND1 CDKN2A EGFR HRAS IL6 KRAS
7 immune system MP:0005387 10.29 CCND1 CDKN2A EGFR FSCN1 IL6 KRAS
8 integument MP:0010771 10.28 CCND1 CDKN2A EGFR FSCN1 HRAS IL6
9 nervous system MP:0003631 10.25 CCND1 CDKN2A EGFR FSCN1 HRAS IL6
10 craniofacial MP:0005382 10.24 CCND1 EGFR HRAS KRAS KRT19 MET
11 neoplasm MP:0002006 10.23 AFP CCND1 CDKN2A EGFR HRAS IL6
12 embryo MP:0005380 10.22 CDKN2A EGFR FSCN1 KRAS KRT19 MET
13 liver/biliary system MP:0005370 10.21 AFP CDKN2A EGFR IL6 KRAS KRT19
14 muscle MP:0005369 10.08 CDKN2A EGFR IL6 KRAS MET SMAD4
15 limbs/digits/tail MP:0005371 10.07 EGFR FSCN1 KRAS MET SMAD4 TP53
16 normal MP:0002873 10.07 CCND1 EGFR HRAS KRAS KRT19 MET
17 no phenotypic analysis MP:0003012 10.01 CDKN2A EGFR HRAS KRAS KRT19 MET
18 renal/urinary system MP:0005367 9.97 EGFR HRAS IL6 KRAS KRT7 MET
19 reproductive system MP:0005389 9.96 AFP CCND1 CDKN2A EGFR IL6 KRAS
20 respiratory system MP:0005388 9.9 CCND1 CDKN2A EGFR FSCN1 HRAS IL6
21 skeleton MP:0005390 9.65 CCND1 CDKN2A EGFR HRAS IL6 KRAS
22 vision/eye MP:0005391 9.28 CCND1 CDKN2A EGFR IL6 KRAS MET

Drugs & Therapeutics for Bile Duct Cancer

Drugs for Bile Duct Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2 Analgesics, Non-Narcotic Phase 4
3 Cyclooxygenase 2 Inhibitors Phase 4
4 Cyclooxygenase Inhibitors Phase 4
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Omega 3 Fatty Acid Phase 4
7 Ulipristal acetate Phase 4 126784-99-4
8
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
11
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
12
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
13
Pembrolizumab Approved Phase 3 1374853-91-4
14
Fluorouracil Approved Phase 3 51-21-8 3385
15
leucovorin Approved Phase 3 58-05-9 6006 143
16
Citalopram Approved Phase 3 59729-33-8 2771
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Analgesics Phase 3
20 Anti-Anxiety Agents Phase 3
21 Antipsychotic Agents Phase 3
22 Narcotics Phase 3
23 Anesthetics, General Phase 3
24 Anesthetics Phase 3
25 Analgesics, Opioid Phase 3
26 Anesthetics, Intravenous Phase 3
27 Antirheumatic Agents Phase 3
28 Anthelmintics Phase 3
29 Antiparasitic Agents Phase 3
30 Alkylating Agents Phase 2, Phase 3
31 Albumin-Bound Paclitaxel Phase 3
32 Folfirinox Phase 2, Phase 3
33 Hematoporphyrin Derivative Phase 3
34 Vitamins Phase 3
35 Micronutrients Phase 3
36 Vitamin B Complex Phase 3
37 Antidotes Phase 3
38 Folate Phase 3
39 Nutrients Phase 3
40 Trace Elements Phase 3
41 Vitamin B9 Phase 3
42 Protective Agents Phase 3
43 Neurotransmitter Agents Phase 3
44 Antidepressive Agents Phase 3
45 Parasympatholytics Phase 3
46 Cholinergic Agents Phase 3
47 Psychotropic Drugs Phase 3
48 Muscarinic Antagonists Phase 3
49 Serotonin Uptake Inhibitors Phase 3
50 Antiparkinson Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 231)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
3 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
4 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
5 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
6 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
7 The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer Recruiting NCT02943031 Phase 4
8 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
9 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
10 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
11 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
12 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
13 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
14 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
15 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
16 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
18 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
19 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
20 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
21 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
22 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
23 A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma Recruiting NCT04003636 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
24 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
25 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy Active, not recruiting NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
26 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
27 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
28 Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
29 A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
30 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
31 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
32 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
33 Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
34 A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
35 A Single-arm, Open-label and Exploratory Clinical Study of PD-1 Monoclonal Antibody SHR-1210 in Combination With GEMOX (Gemcitabine Combined Oxaliplatin) in Patients With Advanced Biliary Tract Cancer Unknown status NCT03486678 Phase 2 SHR-1210+GEMOX
36 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
37 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
38 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed NCT00005938 Phase 2 exatecan mesylate
39 A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
40 Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction Completed NCT00003923 Phase 2 porfimer sodium
41 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
42 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
43 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
44 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
45 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
46 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
47 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
48 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride
49 A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naïve to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
50 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium

Search NIH Clinical Center for Bile Duct Cancer

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Cancer

Anatomical Context for Bile Duct Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bile Duct Cancer:

19
Bile Duct

MalaCards organs/tissues related to Bile Duct Cancer:

40
Liver, Skin, Pancreas, Testes, Lymph Node, T Cells, Lung

Publications for Bile Duct Cancer

Articles related to Bile Duct Cancer:

(show top 50) (show all 2054)
# Title Authors PMID Year
1
Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. 42
32402299 2020
2
The methods of preoperative biliary drainage for resectable hilar cholangiocarcinoma patients: A protocol for systematic review and meta analysis. 42
32481299 2020
3
Identification of potential prognostic long non-coding RNA for predicting survival in intrahepatic cholangiocarcinoma. 42
32221083 2020
4
Significance of mucin expression in pancreatobiliary neoplasms. 54 61
19787286 2010
5
Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report. 61 54
16982466 2006
6
CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. 61 54
16191504 2005
7
Immunohistochemical expression of matrix metalloproteinases in bile duct cancer tissue. 61 54
15682828 2004
8
Down-regulated p16 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. 61 54
11836554 2002
9
Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. 61 54
10873083 2000
10
Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. 61 54
8611434 1996
11
Neural cell adhesion molecule and perineural invasion in gallbladder cancer. 54 61
7844990 1995
12
Neural cell adhesion molecule (NCAM) and perineural invasion in bile duct cancer. 61 54
8501910 1993
13
[Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer]. 54 61
1886576 1991
14
Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. 61
31852273 2020
15
Clinical anatomy of the anterior and posterior hepatic plexuses, including relations with the pancreatic plexus: A cadaver study. 61
31573097 2020
16
Hepatitis B virus infection and the risk of cancer among the Chinese population. 61
32478856 2020
17
Use of washing cytology from removed self-expandable metal stents for biliary strictures: a novel cytology method. 61
32490159 2020
18
Stent graft treatment for ruptured pseudoaneurysms of the splanchnic arteries after pancreaticoduodenectomy: a case report. 61
32488690 2020
19
Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale Towards A Personalized Clinical Application. 61
32527016 2020
20
Synchronous Double Bile Duct Cancers with Distinct Genetic Features. 61
32493852 2020
21
Clinicopathologic and Prognostic Significance of Gallbladder and Cystic Duct Invasion in Distal Bile Duct Carcinoma. 61
31755778 2020
22
Duplication of extrahepatic bile duct with lower common bile duct cancer. 61
32506825 2020
23
Cancer cell selective probe by mimicking EGCG. 61
32173528 2020
24
Dicamba use and cancer incidence in the agricultural health study: an updated analysis. 61
32357211 2020
25
Prognostic Effects of Histology-Based Tumour Microenvironment Scores in Resected Distal Bile Duct Cancer. 61
32473032 2020
26
Clinicopathological significance of olfactomedin-4 in extrahepatic bile duct carcinoma. 61
32276789 2020
27
The Role of Portoenterostomy with Aggressive Hilar Dissection in Biliary Tract Tumors: Report of Case Series and Review of the Literature. 61
32410790 2020
28
[A Case of Liver Metastasis of Distal Bile Duct Cancer]. 61
32389975 2020
29
A Novel Prognostic Score Combining Preoperative Biliary Drainage and Inflammatory Status for Patients with Periampullary Cancers. 61
31062271 2020
30
Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis. 61
31761507 2020
31
Benefits and limitations of middle bile duct segmental resection for extrahepatic cholangiocarcinoma. 61
32037277 2020
32
Identification, recombinant protein production, and functional analysis of a M60-like metallopeptidase, secreted by the liver fluke Opisthorchis viverrini. 61
31901435 2020
33
Embolization for delayed arterial bleeding after percutaneous self-expandable metallic stent placement in patients with malignant biliary obstruction. 61
31778313 2020
34
The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer. 61
32321522 2020
35
Predictors of postoperative early recurrence of extrahepatic bile duct cancer. 61
31549244 2020
36
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel. 61
32489272 2020
37
Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center. 61
31214805 2020
38
Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma. 61
31298745 2020
39
Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis. 61
32343237 2020
40
Statin use and risk of liver cancer: Evidence from two population-based studies. 61
31112291 2020
41
Prognostic impact of the number of metastatic lymph nodes in distal bile duct cancer: An analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. 61
32128955 2020
42
Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea. 61
32249128 2020
43
Systematic Analysis of the Application and Inappropriate Use/Misuse of Statistics in Cholangiocarcinoma Research in Southeast Asia. 61
32102499 2020
44
Mixed adenoneuroendocrine carcinoma of the liver: A rare case report. 61
31929886 2020
45
Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. 61
32140475 2020
46
Proposal of the minimal number of retrieved regional lymph nodes for accurate staging of distal bile duct cancer and clinical validation of the three-tier lymph node staging system (AJCC 8th edition). 61
31633308 2020
47
Comparison of pancreaticoduodenectomy and bile duct resection for middle bile duct cancer: A multi-center collaborating study of Japan and Korea. 61
32048467 2020
48
Two cases of bile duct carcinoma patients who underwent the photodynamic therapy using talaporfin sodium (Laserphyrin®). 61
31222455 2020
49
Unexpected metastasis of intraductal papillary neoplasm of the bile duct without an invasive component to the brain and lungs: A case report. 61
31988595 2020
50
Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center. 61
32021453 2020

Variations for Bile Duct Cancer

Cosmic variations for Bile Duct Cancer:

9 (show top 50) (show all 9120)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94799464 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1495T>C p.S499P 18:25226423-25226423 12
2 COSM94795627 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-1-75G>A p.? 18:25351022-25351022 12
3 COSM127376784 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.4616G>A p.R1539H 8:76851537-76851537 12
4 COSM127371571 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.10571A>C p.K3524T 8:76864285-76864285 12
5 COSM127365243 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*1399G>A p.? 8:76865964-76865964 12
6 COSM127406292 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*345G>T p.? 8:76864910-76864910 12
7 COSM127412310 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1738G>T p.G580* 8:76705826-76705826 12
8 COSM127412300 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-71G>A p.? 8:76681596-76681596 12
9 COSM149327014 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.3003G>A p.L1001= 16:72950682-72950682 12
10 COSM149332377 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.3529+1G>A p.? 16:72829778-72829778 12
11 COSM149275977 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.6964C>T p.R2322* 16:72795718-72795718 12
12 COSM149299892 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*2655C>T p.? 16:72784509-72784509 12
13 COSM143040603 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
14 COSM101978949 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 12
15 COSM101977429 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 12
16 COSM101981179 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 12
17 COSM91375813 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1229T>C p.M410T 11:32396277-32396277 12
18 COSM91384078 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.441C>T p.G147= 11:32434905-32434905 12
19 COSM100002418 VTI1A biliary tract,gallbladder,carcinoma,adenocarcinoma c.*66A>G p.? 10:112815449-112815449 12
20 COSM90480526 USP20 biliary tract,bile duct,carcinoma,adenocarcinoma c.1378C>G p.L460V 9:129869411-129869411 12
21 COSM85193084 U2AF1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.101C>T p.S34F 21:43104346-43104346 12
22 COSM131089175 TSHR biliary tract,gallbladder,carcinoma,adenocarcinoma c.1446C>A p.Y482* 14:81143504-81143504 12
23 COSM87047164 TSC2 biliary tract,gallbladder,carcinoma,adenocarcinoma c.230C>T p.A77V 16:2053346-2053346 12
24 COSM87047147 TSC2 biliary tract,gallbladder,carcinoma,adenocarcinoma c.170G>A p.R57H 16:2050431-2050431 12
25 COSM85721542 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.737+1G>A p.? 9:132921362-132921362 12
26 COSM85726810 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.2551C>T p.Q851* 9:132900789-132900789 12
27 COSM85720859 TSC1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1041G>A p.W347* 9:132911102-132911102 12
28 COSM86229821 TRIM28 biliary tract,bile duct,carcinoma,adenocarcinoma c.1475G>T p.R492L 19:58549053-58549053 12
29 COSM90138864 TRAF7 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1884G>T p.W628C 16:2176270-2176270 12
30 COSM87933529 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.380C>A p.S127Y 17:7675232-7675232 12
31 COSM87921436 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.1015G>T p.E339* 17:7670694-7670694 12
32 COSM88004535 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.717C>G p.N239K 17:7674246-7674246 12
33 COSM87897711 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.818G>A p.R273H 17:7673802-7673802 12
34 COSM87897745 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 12
35 COSM87906561 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.614A>C p.Y205S 17:7674917-7674917 12
36 COSM88042819 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.574C>A p.Q192K 17:7674957-7674957 12
37 COSM87899169 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.993+1G>T p.? 17:7673534-7673534 12
38 COSM87918666 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.535C>A p.H179N 17:7675077-7675077 12
39 COSM87899497 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.586C>T p.R196* 17:7674945-7674945 12
40 COSM87898431 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.451C>T p.P151S 17:7675161-7675161 12
41 COSM88030468 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.568C>G p.P190A 17:7674963-7674963 12
42 COSM87906520 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.726C>T p.C242= 17:7674237-7674237 12
43 COSM87897752 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.731G>A p.G244D 17:7674232-7674232 12
44 COSM87898714 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 12
45 COSM87948469 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.395A>C p.K132T 17:7675217-7675217 12
46 COSM88016238 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.702C>G p.Y234* 17:7674261-7674261 12
47 COSM87913576 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.536A>T p.H179L 17:7675076-7675076 12
48 COSM87899661 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.797G>A p.G266E 17:7673823-7673823 12
49 COSM87956952 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.919+1G>A p.? 17:7673700-7673700 12
50 COSM87898709 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 12

Expression for Bile Duct Cancer

Search GEO for disease gene expression data for Bile Duct Cancer.

Pathways for Bile Duct Cancer

Pathways related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 VEGFA TP53 SMAD4 MET KRAS IL6
2
Show member pathways
13.74 VEGFA TP53 SMAD4 MET KRAS IL6
3
Show member pathways
13.59 VEGFA TP53 SMAD4 MET KRAS IL6
4
Show member pathways
13.56 VEGFA SMAD4 NCAM1 MET KRT7 KRT19
5
Show member pathways
13.41 VEGFA TP53 NCAM1 MET KRAS IL6
6
Show member pathways
13.11 TP53 MET KRAS IL6 HRAS EGFR
7
Show member pathways
13.11 TP53 SMAD4 KRAS IL6 HRAS EGFR
8
Show member pathways
13.06 VEGFA TP53 MET KRAS IL6 HRAS
9
Show member pathways
13 VEGFA TP53 KRAS IL6 HRAS EGFR
10
Show member pathways
12.96 VEGFA MET KRAS HRAS EGFR CCND1
11
Show member pathways
12.94 VEGFA TP53 SMAD4 KRAS HRAS EGFR
12
Show member pathways
12.83 TP53 SMAD4 MET KRAS HRAS EGFR
13 12.82 VEGFA TP53 MET KRAS HRAS EGFR
14
Show member pathways
12.78 VEGFA MET KRAS HRAS EGFR
15
Show member pathways
12.77 TP53 MET KRAS HRAS EGFR
16
Show member pathways
12.75 TP53 MET KRAS HRAS EGFR CDKN2A
17
Show member pathways
12.72 VEGFA KRT19 KRAS HRAS EGFR
18
Show member pathways
12.72 SMAD4 KRAS HRAS EGFR CCND1
19 12.68 VEGFA TP53 SMAD4 MET KRAS IL6
20
Show member pathways
12.65 TP53 KRAS IL6 HRAS EGFR
21
Show member pathways
12.59 VEGFA TP53 MET KRAS IL6 HRAS
22
Show member pathways
12.58 VEGFA TP53 SMAD4 KRAS HRAS EGFR
23
Show member pathways
12.56 TP53 MET KRAS HRAS EGFR
24
Show member pathways
12.52 KRAS IL6 HRAS EGFR CCND1
25
Show member pathways
12.5 TP53 MET KRAS HRAS EGFR
26
Show member pathways
12.44 MET KRAS IL6 HRAS EGFR
27
Show member pathways
12.43 TP53 MET HRAS CCND1
28 12.41 TP53 SMAD4 CDKN2A CCND1
29
Show member pathways
12.38 TP53 IL6 HRAS EGFR CCND1
30 12.37 TP53 KRAS HRAS CDKN2A CCND1
31
Show member pathways
12.37 VEGFA TP53 KRAS HRAS EGFR
32 12.34 TP53 SMAD4 KRAS IL6 HRAS CDKN2A
33
Show member pathways
12.33 TP53 MET KRAS IL6 EGFR
34
Show member pathways
12.31 TP53 MET KRAS HRAS EGFR CCND1
35 12.25 TP53 KRAS IL6 HRAS CDKN2A CCND1
36 12.23 VEGFA TP53 SMAD4 KRAS EGFR CCND1
37
Show member pathways
12.16 SMAD4 KRAS IL6 HRAS EGFR CCND1
38 12.15 SMAD4 KRAS HRAS CCND1
39 12.14 VEGFA NCAM1 MET KRT19 IL6 AFP
40
Show member pathways
12.13 TP53 KRAS HRAS EGFR
41 12.13 TP53 SMAD4 MET CCND1
42 12.12 TP53 MET EGFR AFP
43
Show member pathways
12.11 KRAS HRAS EGFR CCND1
44 12.08 TP53 KRAS HRAS CCND1
45 12.08 VEGFA TP53 IL6 FSCN1 CCND1
46 12.08 VEGFA TP53 SMAD4 KRAS IL6 EGFR
47 12.07 TP53 IL6 EGFR CCND1
48 12.07 VEGFA TP53 MIR21 MET KRAS HRAS
49 12.04 TP53 SMAD4 IL6 HRAS CDKN2A
50 12.03 TP53 SMAD4 KRAS HRAS CDKN2A CCND1

GO Terms for Bile Duct Cancer

Cellular components related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anchored component of membrane GO:0031225 9.26 NCAM1 MSLN CEACAM5 CD24
2 cell surface GO:0009986 9.17 VEGFA NCAM1 MSLN MET EGFR CEACAM5

Biological processes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 VEGFA TP53 SMAD4 MET IL6 HRAS
2 negative regulation of apoptotic process GO:0043066 10.01 VEGFA TP53 MIR21 IL6 EGFR CEACAM5
3 negative regulation of cell proliferation GO:0008285 9.95 TP53 SMAD4 MIR21 IL6 HRAS CDKN2A
4 positive regulation of cell proliferation GO:0008284 9.95 VEGFA MIR21 KRAS IL6 HRAS EGFR
5 MAPK cascade GO:0000165 9.91 NCAM1 MET KRAS HRAS EGFR
6 cytokine-mediated signaling pathway GO:0019221 9.8 VEGFA TP53 KRAS IL6 FSCN1 CCND1
7 positive regulation of gene expression GO:0010628 9.8 VEGFA TP53 MIR21 KRAS IL6 HRAS
8 response to glucocorticoid GO:0051384 9.79 KRAS IL6 CCND1
9 response to estrogen GO:0043627 9.77 KRT19 CD24 CCND1
10 Ras protein signal transduction GO:0007265 9.76 TP53 KRAS HRAS CDKN2A
11 positive regulation of epithelial to mesenchymal transition GO:0010718 9.74 SMAD4 MIR21 IL6
12 positive regulation of epithelial cell proliferation GO:0050679 9.73 VEGFA HRAS EGFR CCND1
13 intrinsic apoptotic signaling pathway GO:0097193 9.7 TP53 HRAS CD24
14 positive regulation of extracellular matrix disassembly GO:0090091 9.61 IL6 FSCN1
15 mitotic G1 DNA damage checkpoint GO:0031571 9.61 TP53 CCND1
16 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.59 MIR21 IL6
17 response to isolation stress GO:0035900 9.58 KRAS HRAS
18 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.58 VEGFA TP53
19 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.56 MIR21 MET
20 response to UV-A GO:0070141 9.55 EGFR CCND1
21 liver development GO:0001889 9.55 MET KRAS HRAS EGFR CCND1
22 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 TP53 IL6 EGFR
23 positive regulation of protein phosphorylation GO:0001934 9.43 VEGFA MIR21 KRAS HRAS EGFR CCND1
24 positive regulation of MAP kinase activity GO:0043406 9.02 VEGFA KRAS HRAS EGFR CD24

Molecular functions related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 VEGFA TP53 SMAD4 NCAM1 MSLN MIR31
2 protein kinase binding GO:0019901 9.55 TP53 EGFR CDKN2A CD24 CCND1
3 protein-containing complex binding GO:0044877 9.35 KRT19 KRAS HRAS EGFR CCND1

Sources for Bile Duct Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....